Endo hands Stendra rights back to struggling Vivus

Vivus ($VVUS) has never had a marketing partner for flailing obesity therapy Qsymia--and now, it's about to be one short for erectile dysfunction therapy Stendra, too. Last week, Endo's ($ENDP) Auxilium Pharmaceuticals announced in a regulatory filing that it would be terminating its licensing pact--covering the U.S. and Canada--with the California drugmaker, with an end date of June 30. Now, Vivus--in desperate need of revenue as it stares down debt and a potential tab for a pricey Qsymia CV trial--will weigh its options and make an announcement by the end of 2016's first quarter as to how the company plans to take the drug forward. More from FiercePharmaMarketing

Read more on